Ann: Successful Completion of In Vitro Studies, page-15

On Brian Leedman: I've followed him for a few years now. He's an excellent salesman and carries a cloud of cred that investors will buy. I've noted that it's worth buying when he joins a company. But also worth selling as soon as the price action starts to look toppy; typically one to three weeks later. As I've said before, I don't believe Brian's presence says anything about the long term prospects of a company.

On NTI: I've followed this one for even longer than I've followed Brian Leedman. But I don't have much to say about the company, its managers, or even its potential product. The original product – the wearable Mente device – is a failure. The original management and scientific team all left in a whirlwind of scandal that destroyed their credibility entirely. So now the company is starting again from zero: new management, new potential product.

On CBD: I'm no expert on cannabinoids, but my understanding of CBD is that it's used as a topical, sublingual, inhalable or edible treatment for a broad variety of ailments, aches, and inflammations. A number of medical studies have been conducted to quantify the efficacy and toxicity of the substance. But I've not seen that CBD is used as a treatment for neuropathy in brain injury, multiple sclerosis, dementia, or autism. I'm happy to follow references if this is a gap in my knowledge.